Gemini Therapeutics has appointed Marc Uknis to serve as its chief medical officer. Uknis was most recently a vice president at Achillion, which was acquired by Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]) last year. His experience also includes positions at ViroPharma and CSL Behring. Cambridge, MA-based Gemini launched in 2017 to develop treatments for age-related macular degeneration. Its lead therapeutic candidate, a recombinant protein called GEM103, is in early-stage testing.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
